Streetbeat News

Analyst Ratings

BARK

Canaccord Genuity analyst Maria Ripps has downgraded BARK (NYSE:BARK) from Buy to Hold and lowered the price target from $3.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:15 pm

ATRA

Mizuho analyst Salim Syed has downgraded Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Neutral and lowered the price target from $31 to $1.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:13 pm

SLVM

Sylvamo (NYSE:SLVM) reported Q3 earnings of $1.70 per share, beating the analyst consensus estimate of $1.33 by 27.82%. However, this is a 32.27% decrease from the same period last year. The company's quarterly sales were $897.00 million, missing the analyst consensus estimate of $905.34 million by 0.92%, and marking a 7.33% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:10 pm

DUOL

Needham analyst Ryan MacDonald has maintained a 'Buy' rating on Duolingo (NASDAQ:DUOL) and raised the price target from $160 to $210.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:09 pm

JRVR

Barclays analyst Tracy Benguigui has downgraded James River Gr Hldgs (NASDAQ:JRVR) from Equal-Weight to Underweight and lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:09 pm

LNSR

LENSAR (NASDAQ:LNSR) reported Q3 losses of $(0.23) per share, beating the analyst consensus estimate of $(0.34) by 32.35%. However, the company's quarterly sales of $9.79 million missed the analyst consensus estimate of $10.20 million by 3.97%. This represents a 26.42% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 12:08 pm

ESS

BMO Capital analyst John Kim has upgraded Essex Property Trust (NYSE:ESS) from Underperform to Market Perform and set a price target of $225.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:07 pm

ECX

ECARX Holdings (NASDAQ:ECX) reported Q3 losses of $(0.11) per share, missing the analyst consensus estimate of $(0.09) by 22.22%. The company also reported quarterly sales of $148.00 million, missing the analyst consensus estimate of $160.36 million by 7.71%.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 12:07 pm

XMTR

Xometry (NASDAQ:XMTR) reported Q3 adjusted EPS of $(0.05), beating the analyst consensus estimate of $(0.12) by 58.33%. However, the company's quarterly sales of $118.93M missed the estimate of $119.97M by 0.87%. This represents a 54.55% increase in EPS and a 14.83% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:06 pm

APYX

Apyx Medical's Q3 earnings per share (EPS) of $(0.13) missed the analyst consensus estimate of $(0.11) by 18.18%. The company's quarterly sales of $11.98 million also fell short of the analyst consensus estimate of $15.37 million by 22.08%. However, both EPS and sales showed an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:04 pm